A practical reference on lyophilization: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-02 and is reviewed periodically as new material appears.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
In addition, Carlos Menem is often accused of having an anti-Peruvian attitude after selling weapons to Ecuador when it was in a war against Peru, generating another accusation of treason against Peruvians after the help that Peruvians gave to Argentina in the Malvinas War. Between 1995 and 2010, diplomatic relations between Argentina and Peru remained frozen at their lowest historical point. Although later the Government of Argentina ended up expressing its reparation to the Peruvian State for this action. While some Peruvian newspapers concluded that Cristina Fernández had complied with what was morally due to the claims of dignity in Peruvian society with those words, other newspapers considered that this had not been enough, coming to suspect a possible camouflaged anti-Peruvian conduct. Examples of such tendencies could be seen in the newspaper Correo, on whose cover the headline "He did not ask for forgiveness" would appear, later pointing out that "Fernández was very cautious in his speech and only used the word 'reparation' in allusion to the questioned sale of arms to Ecuador". Another case was that of Peru 21, which considered that in reality the Argentine president "almost asked for forgiveness".
=== Specific risks/complications === Infection: About 0.9-2.5% of patients who undergo Mohs surgery will develop an infection. This is the most frequently documented adverse event with higher rates in patients who are immunosuppressed. To reduce this risk, antiseptics and antibiotics may be used, but the absolute benefit is modest. Impaired wound healing: Dehiscence (partial reopening of the wound) and necrosis (death of healthy tissue) rates are approximately 1-2%. Risk factors include larger excisions, flap/graft use, and immunosuppressed patients. Complication rates decrease when the wound heals with primary closure (using stitches after surgery) or secondary intention (the wound is left open to heal naturally). Hematoma formation and bleeding: This is most commonly seen in patients on antiplatelet or anticoagulant therapy and occurs in 0.9-1.5% of cases. Despite this, patients are not routinely asked to stop these medications, as most experience no complications, and withdrawal is generally not justified. Scarring: 5-7% of cases, especially larger tumors and complex repairs, result in hypertrophic scarring. Less commonly seen are postoperative swelling, rash, and disturbance of skin sensation. Pain is generally mild. Overall, Mohs surgery is generally safe, with risks/complications being minor and manageable.
=== Overlay === Translucent or sheer fabrics are used to stabilize the textile without altering its appearance. This is typically done using nylon netting, silk crepeline, or polyester Tetex. Overlay is generally applied to textiles too fragile to withstand localized stitching methods. Overlay materials may be stitched to a more stable backing fabric.
Conservative MP Bob Stewart is found guilty of a racially aggravated public order offence after telling an activist to "go back to Bahrain". BBC News reports that Matthew White, the sixth suspect in the murder of Stephen Lawrence, allegedly confessed to involvement in the killing when he tried to stab a security guard while shoplifting from a supermarket in 2015. Sunak warns that protests planned for Armistice Day on 11 November would be "provocative and disrespectful". 4 November A further allegation of sexual assault is made against Russell Brand, dating from 2010. Home Secretary Suella Braverman announces a plan to deter "those who cause nuisance ... by pitching tents in public spaces" by making it harder for homeless people to access tents, describing it as a "lifestyle choice". Around 100 people are injured after a cruise ship, the Spirit of Discovery, owned by Saga Cruises, is caught in a storm in the Bay of Biscay. 6 November Following a trial at Birmingham Crown Court, Mohammed Abbkr is convicted of attempted murder after he set two elderly worshippers alight after they left mosques in London and Birmingham. The Metropolitan Police urges the organisers of pro-Palestinian marches to delay events planned for Armistice Day. 7 November Charles III attends the 2023 State Opening of Parliament, his first as King. Anastrozole, a drug used for a number of years to treat breast cancer, is licensed for use in England as a preventative option. Prince William announces the five winners of the annual Earthshot Prize.
==== Affinity proteomics ==== Affinity proteomics uses antibodies or other affinity reagents (such as oligonucleotide-based aptamers) as protein-specific detection probes. Currently this method can interrogate several thousand proteins, typically from biofluids such as plasma, serum or cerebrospinal fluid (CSF). A key differentiator for this technology is the ability to analyze hundreds or thousands of samples in a reasonable timeframe (a matter of days or weeks); mass spectrometry-based methods are not scalable to this level of sample throughput for proteomics analyses.
Sources: en.wikipedia.org
== History == Progeria was first described in 1886 by Jonathan Hutchinson. It was also described independently in 1897 by Hastings Gilford. The condition was later named Hutchinson–Gilford progeria syndrome. Scientists are interested in progeria partly because it might reveal clues about the normal process of aging.
He found that he could extract some pigments (such as orange carotenes and yellow xanthophylls) from leaves with non-polar solvents, but others (such as chlorophyll) required polar solvents. He reasoned that chlorophyll was held to the plant tissue by adsorption, and that stronger solvents were necessary to overcome the adsorption. To test this, he applied dissolved pigments to filter paper, allowed the solvent to evaporate, then applied different solvents to see which could extract the pigments from the filter paper. He found the same pattern as from leaf extractions: carotene could be extracted from filter paper using non-polar solvents, but chlorophyll required polar solvents. Tsvet's work saw little use until the 1930s.
The source of the fungal contamination in Fleming's experiment remained a speculation for several decades. Fleming suggested in 1945 that the fungal spores came through the window facing Praed Street. This story was regarded as a fact and was popularised in literature, starting with George Lacken's 1945 book The Story of Penicillin. But it was later disputed by his co-workers including Pryce, who testified much later that Fleming's laboratory window was kept shut all the time. Ronald Hare also agreed in 1970 that the window was most often locked because it was difficult to reach due to a large table with apparatuses placed in front of it. In 1966, La Touche told Hare that he had given Fleming thirteen specimens of fungi (ten from his lab) and only one from his lab was showing penicillin-like antibacterial activity. After this, a consensus developed that Fleming's mould had come from La Touche's lab, a floor below Fleming's, as spores which had drifted in through the open doors. Craddock developed severe infection of the nasal antrum (sinusitis) and had undergone surgery. Fleming made use of the surgical opening of the nasal passage and started injecting penicillin on 9 January 1929 but without any effect, probably because the infection was with H. influenzae, a bacterium unsusceptible to penicillin. Fleming gave some of his original penicillin samples to his colleague, surgeon Arthur Dickson Wright for clinical testing in 1928. Although Wright reportedly said that it "seemed to work satisfactorily," there are no records of its use.
== Signs and symptoms == PMOS has a wide variety of signs and symptoms. They include issues with ovulation (such as irregular periods), excess levels of androgens (hormones that trigger male characteristics, such as facial hair growth), and metabolism (such as weight gain). Symptoms usually start in puberty, but may be masked if oral contraceptives are started early. Common signs and symptoms of PMOS are:
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.